Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nacresertib · 3 trials · 2 indications
Cmax of Nacresertib
Tmax of Nacresertib
AUCt of Nacresertib
AUCinf of Nacresertib
Beta of Nacresertib
t1/2 of Nacresertib
Any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
AUCtau of nacresertib
| Arm | Type | Description |
|---|---|---|
| Period 1: Nacresertib Only | EXPERIMENTAL | Participant receives single dose of Nacresertib administered on Day 1 |
| Period 2: Nacresertib and Itraconazole | EXPERIMENTAL | Participant will receive itraconazole multiple times on Day 1, followed by a single dose of itraconazole on Days 2 through 11. Participants will also receive a single oral dose of Nacresertib on Day 4. |
| Nacresertib | EXPERIMENTAL | Participants will receive a single dose of Nacresertib |
| Placebo for Nacresertib | PLACEBO_COMPARATOR | Participants will receive a single dose of Placebo for Nacresertib |
| Part 1: Dose A | EXPERIMENTAL | Participants will receive a single dose of nacresertib or Placebo |
| Part 1: Dose B | EXPERIMENTAL | Participants will receive a single dose of nacresertib or Placebo |
| Part 1: Dose C | EXPERIMENTAL | Participants will receive a single dose of nacresertib or Placebo |
| Part 1: Dose D | EXPERIMENTAL | Participants will receive a single dose of nacresertib or Placebo |
| Part 1: Dose E | EXPERIMENTAL | Participants will receive a single dose of nacresertib or Placebo |
| Part 2: Dose F | EXPERIMENTAL | Participants will receive multiple doses of nacresertib or Placebo |
| Part 2: Dose G | EXPERIMENTAL | Participants will receive multiple doses of nacresertib or Placebo |
| Part 2: Dose H | EXPERIMENTAL | Participants will receive multiple doses of nacresertib or Placebo |
| Name | Type | Description |
|---|---|---|
| Nacresertib | DRUG | Oral Tablet |
| Itraconazole | DRUG | Oral Capsule |
| Placebo for Nacresertib | DRUG | Oral tablet |
| Placebo | DRUG | Oral |
Inclusion Criteria: * Participants must voluntarily sign and date an informed consent, approved by an IEC/IRB, prior to the initiation of any screening or study-specific procedures. * Individuals 18 to 65 years of age at the time of screening. * Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m2 after...
Nacresertib is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in Phase 1 clinical development to assess its safety, tolerability, and how it moves through the body. Its intended therapeutic use has not been established.
Nacresertib is being developed by AbbVie Inc. (NYSE: ABBV). The company is conducting Phase 1 clinical trials to evaluate the drug's safety and pharmacokinetics in healthy adult participants.
Nacresertib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All ongoing and completed studies are early-stage trials in healthy volunteers.
Nacresertib has three Phase 1 trials. NCT07566130 and NCT07600762 are completed studies assessing single and ascending oral doses in healthy adults and Japanese participants. NCT07649954 is recruiting to evaluate how multiple doses of itraconazole interact with Nacresertib.
No alternative names for Nacresertib have been reported. It is identified solely by its investigational name in clinical trial registries and is not known to be marketed under any other brand or chemical name.